nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA1A—Endothelin Pathways—ADCY10—nephrolithiasis	0.0571	0.0934	CbGpPWpGaD
Apraclonidine—ADRA2B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.029	0.0475	CbGpPWpGaD
Apraclonidine—ADRA2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0271	0.0443	CbGpPWpGaD
Apraclonidine—ADRA2B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0244	0.0399	CbGpPWpGaD
Apraclonidine—ADRA1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0237	0.0388	CbGpPWpGaD
Apraclonidine—ADRA2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0228	0.0373	CbGpPWpGaD
Apraclonidine—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.0223	0.0573	CcSEcCtD
Apraclonidine—ADRA2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.022	0.036	CbGpPWpGaD
Apraclonidine—ADRA1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0199	0.0326	CbGpPWpGaD
Apraclonidine—ADRA2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0185	0.0303	CbGpPWpGaD
Apraclonidine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.0171	0.044	CcSEcCtD
Apraclonidine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.0157	0.0405	CcSEcCtD
Apraclonidine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.0153	0.0394	CcSEcCtD
Apraclonidine—ADRA1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.0145	0.0238	CbGpPWpGaD
Apraclonidine—ADRA2C—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.0138	0.0225	CbGpPWpGaD
Apraclonidine—ADRA2B—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0124	0.0202	CbGpPWpGaD
Apraclonidine—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0306	CcSEcCtD
Apraclonidine—ADRA2C—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0115	0.0189	CbGpPWpGaD
Apraclonidine—ADRA2A—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.0112	0.0183	CbGpPWpGaD
Apraclonidine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0288	CcSEcCtD
Apraclonidine—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.011	0.0283	CcSEcCtD
Apraclonidine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.0109	0.028	CcSEcCtD
Apraclonidine—ADRA2C—Integration of energy metabolism—CHRM3—nephrolithiasis	0.0108	0.0177	CbGpPWpGaD
Apraclonidine—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0278	CcSEcCtD
Apraclonidine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0272	CcSEcCtD
Apraclonidine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00981	0.0252	CcSEcCtD
Apraclonidine—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00956	0.0246	CcSEcCtD
Apraclonidine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00938	0.0241	CcSEcCtD
Apraclonidine—ADRA2A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00938	0.0153	CbGpPWpGaD
Apraclonidine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00936	0.0241	CcSEcCtD
Apraclonidine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00928	0.0239	CcSEcCtD
Apraclonidine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00901	0.0232	CcSEcCtD
Apraclonidine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00887	0.0228	CcSEcCtD
Apraclonidine—ADRA2A—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00879	0.0144	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00877	0.0143	CbGpPWpGaD
Apraclonidine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00862	0.0222	CcSEcCtD
Apraclonidine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00857	0.0221	CcSEcCtD
Apraclonidine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00845	0.0217	CcSEcCtD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00819	0.0134	CbGpPWpGaD
Apraclonidine—ADRA1A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00819	0.0134	CbGpPWpGaD
Apraclonidine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00814	0.0209	CcSEcCtD
Apraclonidine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00814	0.0209	CcSEcCtD
Apraclonidine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00804	0.0207	CcSEcCtD
Apraclonidine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00796	0.0205	CcSEcCtD
Apraclonidine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.0078	0.0201	CcSEcCtD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00732	0.012	CbGpPWpGaD
Apraclonidine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00711	0.0183	CcSEcCtD
Apraclonidine—ADRA1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.0071	0.0116	CbGpPWpGaD
Apraclonidine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00705	0.0182	CcSEcCtD
Apraclonidine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.007	0.018	CcSEcCtD
Apraclonidine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00695	0.0179	CcSEcCtD
Apraclonidine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00693	0.0178	CcSEcCtD
Apraclonidine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00672	0.0173	CcSEcCtD
Apraclonidine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00667	0.0172	CcSEcCtD
Apraclonidine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00667	0.0172	CcSEcCtD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00665	0.0109	CbGpPWpGaD
Apraclonidine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00643	0.0165	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00638	0.0164	CcSEcCtD
Apraclonidine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00617	0.0159	CcSEcCtD
Apraclonidine—ADRA1A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00592	0.00968	CbGpPWpGaD
Apraclonidine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00575	0.0148	CcSEcCtD
Apraclonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0056	0.00916	CbGpPWpGaD
Apraclonidine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.0056	0.0144	CcSEcCtD
Apraclonidine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00552	0.0142	CcSEcCtD
Apraclonidine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00534	0.0137	CcSEcCtD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00529	0.00866	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00523	0.00856	CbGpPWpGaD
Apraclonidine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00516	0.0133	CcSEcCtD
Apraclonidine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00496	0.0128	CcSEcCtD
Apraclonidine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00491	0.0126	CcSEcCtD
Apraclonidine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00489	0.0126	CcSEcCtD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.0048	0.00785	CbGpPWpGaD
Apraclonidine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00463	0.0119	CcSEcCtD
Apraclonidine—ADRA1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00457	0.00748	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—SLC7A9—nephrolithiasis	0.00452	0.00739	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—DGKH—nephrolithiasis	0.00452	0.00739	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00448	0.00733	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00425	0.00695	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—RGS14—nephrolithiasis	0.00423	0.00692	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—DGKH—nephrolithiasis	0.00422	0.00691	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—SLC7A9—nephrolithiasis	0.00422	0.00691	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.00395	0.00646	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00392	0.00641	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—RGS14—nephrolithiasis	0.00384	0.00628	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00365	0.00598	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00364	0.00596	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—RGS14—nephrolithiasis	0.00359	0.00587	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00345	0.00565	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—DGKH—nephrolithiasis	0.00343	0.00561	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SLC7A9—nephrolithiasis	0.00343	0.00561	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.00341	0.00558	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—PTH—nephrolithiasis	0.00334	0.00547	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00321	0.00525	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—RGS14—nephrolithiasis	0.00314	0.00513	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—PTH—nephrolithiasis	0.00312	0.00511	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00298	0.00488	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00291	0.00477	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00286	0.00467	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.00277	0.00454	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—PTH—nephrolithiasis	0.00273	0.00446	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.00267	0.00436	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADCY10—nephrolithiasis	0.00267	0.00436	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—DGKH—nephrolithiasis	0.00259	0.00424	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—PTH—nephrolithiasis	0.00254	0.00415	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GRHPR—nephrolithiasis	0.00253	0.00415	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADCY10—nephrolithiasis	0.00249	0.00408	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—DGKH—nephrolithiasis	0.00242	0.00396	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.00233	0.00382	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RGS14—nephrolithiasis	0.00227	0.00371	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AGXT—nephrolithiasis	0.00226	0.00369	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADCY10—nephrolithiasis	0.00218	0.00356	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.00217	0.00355	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RGS14—nephrolithiasis	0.00212	0.00347	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—DGKH—nephrolithiasis	0.00212	0.00346	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00207	0.00338	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GRHPR—nephrolithiasis	0.00206	0.00337	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADCY10—nephrolithiasis	0.00202	0.00331	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—DGKH—nephrolithiasis	0.00197	0.00322	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00193	0.00316	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—SLC26A1—nephrolithiasis	0.00192	0.00314	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APRT—nephrolithiasis	0.00192	0.00314	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PTH—nephrolithiasis	0.00189	0.00309	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CHRM3—nephrolithiasis	0.00188	0.00307	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RGS14—nephrolithiasis	0.00185	0.00303	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AGXT—nephrolithiasis	0.00183	0.003	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PTH—nephrolithiasis	0.00176	0.00289	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.00175	0.00287	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RGS14—nephrolithiasis	0.00172	0.00282	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PTH—nephrolithiasis	0.00172	0.00281	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00169	0.00276	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PTH—nephrolithiasis	0.0016	0.00262	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00157	0.00256	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APRT—nephrolithiasis	0.00156	0.00255	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SLC26A1—nephrolithiasis	0.00156	0.00255	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PTH—nephrolithiasis	0.00154	0.00252	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00153	0.00251	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DGKH—nephrolithiasis	0.00153	0.00251	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CHRM3—nephrolithiasis	0.00153	0.00251	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PTH—nephrolithiasis	0.00143	0.00234	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DGKH—nephrolithiasis	0.00143	0.00234	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00143	0.00234	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.00142	0.00233	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PTH—nephrolithiasis	0.0014	0.00229	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AQP1—nephrolithiasis	0.00137	0.00224	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PTH—nephrolithiasis	0.0013	0.00213	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00125	0.00205	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DGKH—nephrolithiasis	0.00125	0.00205	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CHRM3—nephrolithiasis	0.00124	0.00202	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DGKH—nephrolithiasis	0.00116	0.0019	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00116	0.0019	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AQP1—nephrolithiasis	0.00111	0.00182	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CHRM3—nephrolithiasis	0.00111	0.00181	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CHRM3—nephrolithiasis	0.00103	0.00169	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTH—nephrolithiasis	0.00101	0.00166	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CHRM3—nephrolithiasis	0.00101	0.00164	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTH—nephrolithiasis	0.000947	0.00155	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CHRM3—nephrolithiasis	0.000905	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000841	0.00137	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTH—nephrolithiasis	0.000827	0.00135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTH—nephrolithiasis	0.000769	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SPP1—nephrolithiasis	0.000509	0.000832	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SPP1—nephrolithiasis	0.000475	0.000777	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SPP1—nephrolithiasis	0.000415	0.000679	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPP1—nephrolithiasis	0.000386	0.000631	CbGpPWpGaD
